Cholesterol lowering effects of soy protein, and how denatured protein may increase the risk for cardiovascular disease by Høie, Lars Henrik
  
 
 
 
 
 
 
Cholesterol lowering effects of soy protein, 
and how denatured protein may increase 
the risk for cardiovascular disease. 
 
 
 
by 
 
 
Lars Henrik Høie, M.D. 
 
 
 
 
 
 
 
 
 
 
 
Domus & Medicus 
Pilestredet Park 7 
N-0176 Oslo, Norway 
 
 
 
 
 
June 2010
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Lars Henrik Høie, 2011 
 
 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 1078 
 
ISBN 978-82-8264-053-4 
 
 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
 
 
 
 
 
 
 
 
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AIT Oslo AS.  
 
Produced in co-operation with Unipub.  
The thesis is produced by Unipub merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
 

  
                                        
 
 
 
 
 
 
                                        
 
                           
                           This thesis is dedicated to: 
 
 
                                 Lisbet, Celine & Nicola  
 
                                                Else & Kåre 
 
                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                                    Acknowledgements 
 
 
I am very grateful for the important feedback and comments to this thesis from:  
Professor Dag Bruusgaard at the University of Oslo   
Professor Anders Goksøyr at the University of Bergen  
Nicole Armbruester for searching literature. 
 
To the medical doctors who have made their important contributions to the clinical research 
presented in this material at:  
Aarhus and Gentofte University Hospitals (Denmark)  
Helsinki University Hospital (Finland)  
Karolinska Institutet (Stockholm, Sweden) 
Potsdam & Humbolt University Hospitals (Berlin, Germany).  
 
To the scientists involved in the protein based product developments at:  
Prinsen bv (Holland)  
Campden & Chorleywood (England)  
Norwegian University of Life Sciences (Norway)  
TetraPak (Lund, Sweden). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Contents 
 
1  DEDICATIONS...............................................................................................2  
2 ACKNOWLEDGEMENTS.............................................................................3  
3 CONTENTS..................................................................................................... 4 
4 SUMMARY ....................................................................................................... 5 
5  INTRODUCTION ........................................................................................... 6 
6  HYPERCHOLESTEROLEMIA ................................................................... 8 
6.1 DEFINITION OF HYPERCHOLESTEROLEMIA ............................................................... 8 
6.2 AETIOLOGY OF HYPERCHOLESTEROLEMIA .............................................................. 9 
6.3 TREATMENT OF HYPERCHOLESTEROLEMIA ............................................................ 10 
7  SOY-BASED DIETS ..................................................................................... 15 
8  LIPID LOWERING EFFECT OF SOY ..................................................... 16 
9  OBJECTIVES OF THE THESIS ................................................................ 17 
10  MATERIALS AND METHODS ............................................................... 17 
11  RESULTS ..................................................................................................... 21 
11.1   SUMMARIES OF ARTICLES .......................................................................................... 21 
Article 1 ................................................................................................................................................. 21 
Article 2 ................................................................................................................................................. 21 
Article 3 ................................................................................................................................................. 22 
Article 4 ................................................................................................................................................. 23 
Article 5 ................................................................................................................................................. 23 
Article 6 ................................................................................................................................................. 24 
       11.2  SUMMARY OG THE RESULTS….....………………………………………………25 
12  DISCUSSION ............................................................................................... 26 
12.1           DESIGN ............................................................................................................... 26 
12.2 WEAKNESSES, STRENGTHS, ARGUMENTS ............................................................... 26 
12.3 PATIENTS............................................................................................................... 27 
12.4 EFFICACY .............................................................................................................. 27 
12.5 SAFETY ................................................................................................................. 20 
13 CONCLUSIONS .................................................................................... 31 
14 REFERENCES ....................................................................................... 33 
15 PUBLISHED ARTICLES ..................................................................... 43 
 - 5 - 
 
4  Summary 
    
  The Food and Drug Administration (FDA) in the U.S. approved a health claim for soy pro-
tein in October 1999, i.e. that the intake of 25 g soy protein per day, or 6,25 g soy protein 
per serving, may prevent coronary artery disease by lowering cholesterol. The Joint Health 
Claims Initiative (JHCI) approved a similar health claim in the U.K. in 2002.  
    We have in this thesis confirmed that soy protein significantly lowers LDL, total choles-
terol and other risk factors for cardiovascular disease (CVD), and that adding soy phospho-
lipids and soy fiber doubles these lipid lowering properties. Surprisingly, we have docu-
mented that processing of soy protein using ultra heat treatment (UHT) not only ruins the 
cholesterol lowering effect of soy protein, but significantly increases blood lipids, with an 
approximately 20% increase in both LDL and total cholesterol after 8 weeks intake of 25 g 
soy protein per day. The same increases in serum lipids were found in the UHT treated milk 
protein based placebo beverage. UHT treated proteins are thereby potentially atherogenic, 
and may increase the risk for CVD.   
  By showing that denatured proteins may increase the risk for CVD, we have found a paral-
lel with regards to fat processing resulting in trans fatty acids, which have been documented 
to increase the risk of CVD.  
 Our research has shown a potential increased CVD risk using high temperature treated pro-
tein beverages, such as UHT treated soy milk, milk & flavoured milk protein drinks, and soy 
protein based beverages - products which are used regularely by large consumer groups. Our 
results may thereby have important implications for consumers, legislators and for the food 
and beverage industries. These new and unexpected  results were supported by a study 
where we developed a new non-denatured soy protein, which doubled serum lipid reduc-
tions compared to a conventional soy protein. The most likely explanation for our findings is 
that a) high temperature denatures proteins, and that b) bioactive peptides from digestion are 
altered, thereby becoming atherogenic.  
  Legislators including the FDA and JCHI may eventually revise their health claims for soy 
protein, and make these claims more specific, based on clinical documentation from manu-
facturers of soy protein regarding to lipid reductions. Ethanol is e.a. used by some of the soy 
producers in the processing of soy protein, and since alcohol denatures protein, ethanol 
processed soy proteins may also turn out to be atherogenic. If detrimental to health, possible 
health warnings may be considered by health authorities if UHT has been used in the 
processing of protein. 
  The studies in this thesis have been conducted in cooperation with medical doctors and 
other scientists at university hospitals in Aarhus, Copenhagen, Helsinki, Stockholm and Ber-
lin, while the protein based product developments have been conducted in Holland, Eng-
land, Norway and Sweden. 
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5  Introduction 
According to the WHO, an estimated 17.5 million people died from cardiovascular dis-
ease (CVD) in 2005 worldwide, representing 30% of all deaths globally. Of these deaths, 7.6 
million were due to heart attacks and 5.7 million were due to stroke.  
Hypercholesterolemia, elevation of cholesterol, particularly low-density lipoprotein 
(LDL) levels in the blood, is known to increase the risk of CVD (1), which include coronary 
heart disease (heart attacks), cerebrovascular disease (stroke), peripheral artery disease and 
heart failure. 
Increased lipid levels can lead to a build-up of fat deposits in the arterial walls. The blood 
vessels become narrower and less flexible, with a reduction of blood flow to the heart and 
brain. Blood vessels may thereby be blocked by blood clots, causing an insufficient supply 
of blood to the heart or the brain, which leads to heart attack or stroke (1). 
Often, the underlying blood vessel disorders show no symptoms. A heart attack or stroke 
may be the first warning signs of the disease. According to EUROPSIRE, the prevalence of 
elevated total cholesterol (≥ 194 mg/dL,5.01 mmol/L) in patients with established coronary 
heart disease is 58.5% (2). 
Since a 10% reduction in total cholesterol lowers the risk of cardiovascular events by up 
to 50% for older subjects with mild-to-moderate hypercholesterolemia, cholesterol lowering 
therapies are important (3, 4). LDL (low-density lipoprotein) cholesterol is regarded as the 
major atherogenic lipoprotein and has been identified by the NCEP (National Cholesterol 
Education Program) to be the primary target for cholesterol-lowering therapy (5).  
Aside from genetic factors, which are regarded as the primary cause of hypercholestero-
lemia, food patterns also contribute to its prevalence. Dietary behavior has changed consi-
derably in recent years. It has been demonstrated, that the average consumption of starch 
and complex carbohydrates has decreased, whereas the intake of fat, trans fatty acids and 
saturated fat, as well as simple carbohydrates has increased (6). Increased consumption of 
snacks and fast food, typically containing a high percentage of fat, has been observed in re-
cent years. A sedentary lifestyle also contributes to a greater prevalence of elevated blood 
cholesterol levels. 
The economic implications of hypercholesterolemia, increasing the risk of CVD, are im-
portant.  In Europe, CVD is estimated to cost the EU 192 billion € per year (7). Compared to 
this the 2008 EU budget allocation to health care is 129.1 billion €. 57% of expenses related 
to CVD in the EU are due to direct health care cost, 21% to productivity loss and 22% to 
informal care for people with CVD. 
Treatment of elevated plasma cholesterol concentrations includes dietary intervention, 
exercise programs, and drug treatment. 
Dietary changes are the most important non-pharmacological measures to reduce serum 
lipid levels. Changed dietary patterns have an influence on modifying blood cholesterol le-
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vels, which has been documented in many clinical investigations. Reducing the intake of 
saturated fat and trans fatty acids are regarded the most successful dietary approach.  
Several studies have shown the beneficial effects of cholesterol-lowering foods, which 
are becoming increasingly important in the treatment of hypercholesterolemia and the reduc-
tion of CVD risk (8, 9). The intake of dietary supplements may be an alternative in individu-
als with moderately increased lipid values, which cannot be normalized by lifestyle modifi-
cations such as dietary changes and exercise. Soy-based supplements play a role in this con-
text. Soy protein has been shown to reduce the risk of heart disease by lowering serum cho-
lesterol levels. The U.S. Food and Drug Administration (FDA) approved the following 
health claim in 1999:”Diets low in saturated fat and cholesterol that include 25 g of soy pro-
tein per day may reduce the risk of heart disease.” 
A meta-analysis of 38 clinical trials concluded that the consumption of soy protein signif-
icantly decreases concentrations of total cholesterol, LDL cholesterol and triglycerides in the 
blood (11). Soy-based products have documented significant lipid reductions based on a 
composition of soy components such as isolated soy protein with high-standardized levels of 
isoflavones, cotyledon soy fiber and soy phospholipids (12, 13).  
The mechanisms of the lipid-lowering effects of soy protein are still unclear, although 
there are possible explanations that need further investigation. Nevertheless, the use of soy-
based diets has shown good efficacy and tolerability. A study investigating the willingness 
of people to consume soy foods for lowering cholesterol revealed that most of the partici-
pants were willing to consume soy as part of lifestyle modification to prevent CVD (14).  
Many different soy products are currently on the market, and their cholesterol lowering 
properties may differ. The aim of this thesis is to examine the efficacy and safety of soy pro-
tein based products with regards to lowering lipid levels in the blood. Special focus is given 
to exploring the impact of processing on the cholesterol lowering properties of soy protein 
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6  Hypercholesterolemia 
6.1 Definition of hypercholesterolemia 
Hypercholesterolemia is defined as elevated levels of cholesterol. Cholesterol is a lipid 
which, together with cholesterol esters, phospholipids, and triglycerides, is transported in the 
blood as part of larger molecules called lipoproteins. They can be assigned to different cate-
gories and the five major families of lipoproteins are low-density lipoproteins (LDL), high-
density lipoproteins (HDL), very low-density lipoproteins (VLDL), intermediate-density 
lipoproteins (IDL), and chylomicrons (15).  
LDL cholesterol normally makes up 60-70% of total serum cholesterol and contains a 
single apolipoprotein, apo B-100 (apo B) that surrounds the fatty acids, keeping them so-
luble in the aqueous environment. In general, LDL transports cholesterol and triglycerides 
from the liver to peripheral tissues and regulates cholesterol synthesis at these sites. LDL 
cholesterol is well known to increase the risk of coronary heart disease (CHD) because it 
can be retained in arteries by arterial proteoglycans starting the formation of arterial plaques 
(16). Increased levels are associated with artherosclerosis, and thereby heart attack, stroke, 
and peripheral vascular disease. 
In contrast, HDL cholesterol is inversely correlated to the risk of CVD. HDL normally 
carries around 20-30% of total serum cholesterol. Apo A-I and apo A-II are the major apoli-
poproteins of HDL (17).  
Another lipoprotein subclass is VLDL, which is rich in triglycerides. They account for 
10-15% of total serum cholesterol and are assembled in the liver from cholesterol and apoli-
poprotein. In the bloodstream it is converted to LDL, therefore it is a precursor of LDL. The 
intermediate lipoproteins IDL, reside between VLDL and LDL, but are included in LDL 
measurements in clinical practice (15, 18). 
The fifth class of blood lipoproteins is chylomicrons, which are triglyceride-rich lipo-
proteins formed in the intestine from dietary fat and which appear in the blood after a fat-
containing meal (18).  
Table 1 presents different types of hypercholesterolemia classified according to Fredrick-
son (19), based on the pattern of lipoproteins on electrophoresis or ultracentrifugation. This 
classification system has been adopted by the WHO.  
Hypercholesterolemia does not lead to specific symptoms and is usually discovered dur-
ing routine medical tests or examinations for atherosclerotic cardiovascular disease. Some-
times xanthomas, deposits of cholesterol, can be found in individuals with hereditary forms 
of the disorder or in people with high levels of cholesterol. Deposits are especially found 
around the eyes or along the achilles tendon (20). 
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Table 1: Fredrickson Classification of Lipid Disorders (19) 
Type Associated clinical disorders Labs description 
Type I decreased lipoprotein lipase (LPL) or altered ApoC2 elevated chylomicrons 
Type IIa LDL receptor deficiency elevated LDL only 
Type IIb decreased LDL receptor and increased ApoB 
elevated LDL and VLDL 
and triglycerides 
Type III defect ApoE synthesis increased IDL 
Type IV increased VLDL production and decreased elimination increased VLDL 
Type V increased VLDL production and decreased lipoprotein lipase 
increased VLDL and  
chylomicrons 
 
It is well documented that lipid disorders are associated with an increased risk of coro-
nary heart disease, stroke and peripheral arterial disease. This is because excess cholesterol 
contributes to atherosclerosis, which eventually leads to CVD. Since LDL cholesterol is 
regarded as a high risk factor for CVD, LDL has been labeled “bad” cholesterol (16). In 
contrast, increased levels of HDL cholesterol are commonly assumed to reduce the risk of 
CVD and is therefore regarded as “good” cholesterol (21, 22). 
 
6.2 Aetiology of hypercholesterolemia 
There are both primary (genetic) and secondary causes of elevated cholesterol levels in 
the blood. Primary causes are single or multiple genetic mutations that result in an over pro-
duction or defective clearance of triglycerides and LDL cholesterol, or in an underproduc-
tion or excessive clearance of HDL. Primary lipid disorders are common in patients who 
develop physical signs of hypercholesterolemia such as xanthomas, onset of premature   
atherosclerotic disease (age<60), a family history of atherosclerosis, or elevated serum cho-
lesterol >240 mg/dL (>6.20 mmol/L) (23). In children, primary disorders are the most com-
mon cause (23). 
In contrast, secondary causes contribute to most cases of hypercholesterolemia in adults.  
The most important secondary cause in developed countries is a sedentary lifestyle with 
excessive dietary intake of saturated fat, cholesterol, and trans fatty acids (23).  
Other secondary causes are diabetes mellitus and risk factors in the metabolic syndrome, 
nephrotic syndrome, hypothyroidism, anorexia nervosa, Zieve’s syndrome, excessive alco-
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hol intake and drugs such as thiazides, -blockers, retinoids, active antiretroviral agents and 
glucocorticoids (23).  
Among these factors, diabetes is of special concern, because diabetics tend to have an 
atherogenic combination of increased levels of triglycerides, elevated small, dense LDL 
fractions and low HDL. One explanation may be that this combination of lipoproteins is 
caused by obesity and/or poor control of diabetes, which increases circulating fatty acids, 
leading to an increased hepatic VLDL production. Triglyceride-rich VLDL transfers trigly-
cerides and cholesterol to LDL and HDL cholesterol, initiating the formation of triglyceride-
rich, small dense LDL cholesterol and clearance of triglyceride-rich HDL cholesterol. Di-
abetic related hypercholesterolemia is often associated with increased caloric intake and 
physical inactivity. A high prevalence of hypercholesterolemia in insulin-dependent diabetes 
mellitus has been documented in several clinical studies (24, 25).  
 
6.3     Treatment of hypercholesterolemia 
In most western and industrialized countries, increased lipid levels are widespread. Data 
based on the Third National Health and Nutrition Examination Survey (NHANES III) 
showed that approximately 28% of the US population, or more than 50 million adults over 
20 years of age suffer from hypercholesterolemia which warrants treatment (5). With respect 
to specific subpopulations, it was found that approximately 29% of caucasians, 24% of 
blacks, and 18% of hispanics were qualified for cholesterol-lowering treatment. The preva-
lence varies slightly between women and men: 30% of men and 26% of women need lipid-
lowering treatment according to the National Cholesterol Education Program Adult Treat-
ment Panel II (NCEP ATP II) criteria (26).  
Another survey in Argentina revealed that one third of the population age 20 or older is 
affected by hyperlipidemia and hypertension (27). 
Treatment of hypercholesterolemia depends on several factors such as lipid levels, indi-
vidual heart risk factors and general health.  
A desirable total cholesterol level is usually less than 200 mg/dL (5.17 mmol/L) (4). A 
level of 200 to 239 mg/dL (5.17-6.18 mmol/L) is borderline high, while a value greater than 
equal to 240 mg/dl (6.20 mmol/L) is considered to be high. Tables 2 and 3 summarize the 
classifications of lipids in blood.  
The most important factor in treating lipid disorders is to reduce LDL cholesterol levels.  
Initially, it is reasonable to attempt to lower cholesterol levels by reducing dietary cholester-
ol intake. 
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Table 2: ATP III Classification of total cholesterol and LDL cholesterol (5) 
Total Cholesterol in mg/dL (mmol/L) LDL Cholesterol in mg/dL (mmol/L) 
  < 100 (< 2.58) Optimal 
< 200 (< 5.17) Desirable 100-129 (2.58-3.33) Near optimal/above optimal 
200-239 (5.17-6.18) Borderline High 130-159 (3.36-4.11) Borderline High 
≥ 240 (≥ 6.20) High 160-189 (4.13-4.88) High 
  ≥ 190 (≥ 4.91) Very High 
 
 
Table 3: ATP III Classification of serum triglycerides and HDL cholesterol (5) 
Triglyceride Category in mg/dL (mmol/L) HDL Cholesterol in mg/dL (mmol/L) 
< 150 (< 1.70) Normal   
150-199 (1.70-2.25) Borderline High < 40 (< 1.03) Low 
200-499 (2.26-5.64) High ≥ 60 (≥ 1.55) High 
≥ 500 (≥ 5.65) Very High   
 
The American Heart Association (AHA) and other standard guidelines recommend the 
following measures (28): 
 A diet that lowers caloric intake and reduces total fat and cholesterol intake 
 Limiting daily fat intake to no more than 30% of total calories 
 Cholesterol intake should be less than 300 mg daily 
 Carbohydrate intake should total 55% to 60% of total daily calories 
 Avoiding foods high in sugar 
 Fiber intake from foods, not supplements, should total 25 to 30 grams daily 
 Use of mono-saturated oils such as olive or canola oil 
 Intake of five or more servings of fruit and vegetables daily 
 Additional intake of antioxidants, vitamin C, beta-carotene and vitamin E in         
recommended amounts 
A meta-analysis of large international nutrition studies revealed a mean decrease of cho-
lesterol of only 2% with this dietary approach (29). Therefore, other lifestyle changes such 
as regular exercise (30), smoking cessation (31, 32, 33) and reduction of excessive alcohol 
intake should preferably also be implemented. Interestingly, soy protein is not mentioned, in 
spite of the approved health claim by the FDA. 
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It is important to identify and treat any potential underlying medical problems, such as 
hyperthyroidism and diabetes, which may cause or contribute to hypercholesterolemia. 
If optimal lipid levels cannot be achieved by a dietary approach, the administration of li-
pid-lowering drugs should be considered. Such drugs are statins, bile acid sequestrants, fi-
brates and niacin (vitamin B3). Each category of medication has its own mode of action, 
cost and efficacy.  
The most powerful lipid-lowering drugs are statins, which reduce the production of cho-
lesterol in the liver. They work by inhibiting hydroxymethylglutaryl CoA reductase, which 
functions as a key enzyme in cholesterol synthesis (34). Using statins can reduce LDL cho-
lesterol concentrations by as much as 30 to 50% (35), and is widely used. 
Bile acid sequestrants, including colesevelam, colestipol, and cholestyramine, bind bile 
acids in the intestine and thereby reduce dietary cholesterol absorption. Bile acid seques-
trants are mainly prescribed for the treatment of mild to moderate LDL cholesterol eleva-
tion, and are normally used with statins or with niacin (36, 37). 
Niacin is a B-vitamin which lowers levels of both VLDL and LDL cholesterol and raises 
HDL cholesterol level. Fibrates, another category of lipid-lowering drugs, favorably alter 
lipid metabolism, resulting in lower triglyceride concentrations and higher HDL cholesterol 
(38). 
All lipid-lowering drugs can be regarded as being effective, but their use may be accom-
panied by adverse events, such as muscle weakness, bloating, nausea, cramping and liver 
damage (39, 40, 41, 42).  
Alternatives to such medications are dietary interventions such as restriction of the intake 
of saturated fatty acids (43, 44, 45) and trans fatty acids (46, 47), and increased intake of 
dietary fiber and protein-rich legumes, preferably soybeans (48, 49). Plant-sterols are also an 
effective dietary adjuvant (50, 51). In contrast to statins, sterols act by blocking the absorp-
tion of cholesterol in the intestine (52, 53). It has been shown, that the combination of ste-
rols with other dietary components reduce elevated blood lipid levels, thereby providing an 
alternative treatment to medication (54). 
The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP 
III) guidelines are the most common reference when deciding who should be treated for 
hyperlipidemia (5). 
Table 4, gives an overview of risk categories with corresponding LDL levels and medical 
treatment and goals. 
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Table 4: National Cholesterol Education Program Adult Treatment Panel III Guidelines for Treat-
ment of Hyperlipidemia, CAD = coronary artery disease (5) 
Risk Category Begin Lifestyle Changes If: 
Consider Drug Therapy 
If: LDL Goal 
High: CAD or CAD 
equivalents  
10-yr risk > 20% 
LDL ≥ 100 mg/dL  
(≥ 2.58 mmol/L) 
LDL ≥ 100 mg/dL  
(≥ 2.58 mmol/L) 
(drug optional if < 100 mg/dL  
(< 2.58 mmol/L))  
< 100 mg/dL  
(< 2.58 mmol/L); 
< 70 mg/dL 
(< 1.81 mmol/L) 
optional 
Moderate high:  
≥ 2 risk factors with  
10-yr risk 10 to 20% 
LDL ≥ 130 mg/dL 
(≥ 3.36 mmol/L) 
LDL ≥ 130 mg/dL 
(≥ 3.36 mmol/L) 
< 130 mg/dL  
(< 3.36 mmol/L);  
< 100 mg/dL  
(< 2.58 mmol/L)  
optional 
Moderate:  
≥ 2 risk factors with  
10-yr risk < 10% 
LDL ≥ 130 mg/dL 
(≥ 3.36 mmol/L) 
LDL ≥ 160 mg/dL 
(≥ 4.13 mmol/L) 
< 130 mg/dL  
(< 3.36 mmol/L);  
< 100 mg/dL 
(< 2.58 mmol/L);  
optional 
Lower: 0-1 risk factor LDL ≥ 160 mg/dL (≥ 4.13 mmol/L) 
LDL ≥ 190 mg/dL  
(≥ 4.91 mmol/L) 
(drug optional if 160-189 
mg/dL (4.13-4.88 mmol/L)) 
< 160 mg/dL 
(< 4.13 mmol/L) 
 
Recent studies show that awareness and acceptance of the guidelines is high among prac-
titioners, but implementation can be improved (56).  
Another important issue is the compliance of patients during treatment of hyperlipidemia. 
Patients who need lipid-lowering therapy are likely to need it long-term, in many cases for 
life. However, many patients do not adhere to the recommended lifestyle modification or 
prescribed medication regimen (57). Hypercholesterolemia often does not have any symp-
toms and is often discovered during routine examinations (58, 59). Hence, people who need 
lipid-lowering therapy must be detected, e.g. by screening programs. 
Several screening guidelines have been developed, which differ mainly in their recom-
mendations concerning age to start screening, the best time interval between testing, and the 
age at which screening may stop. 
The United States Preventive Task Force recommends the following: 
 Lipid screening should start at age 35 in men and at age 45 in women. 
 Screening is recommended for men aged 20 to 35 and for women aged 20 to 40 in 
patients with diabetes, a family history of cardiovascular disease before the age of 50 
in male relatives or age 60 in female relatives, a family history of hyperlipidemia, or 
multiple coronary heart disease risk factors, such as smoking or hypertension. 
 Screening should include total cholesterol and HDL cholesterol levels, and can be 
measured on non-fasting and fasting samples. 
 The optimal time interval between screenings is uncertain; reasonable options in-
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clude every five years, with a shorter interval for those with high-normal lipid levels 
and longer intervals for low-risk individuals with low or normal levels. 
 The age to stop screening has not been established. 
 Screening may be appropriate in older people who have never been screened, but re-
peated screening is less important in older people because lipid levels are less likely 
to increase after the age of 65. 
 Treatment decisions should take into account the overall risk of heart disease, rather 
than lipid levels alone. 
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7   Soy products 
Soybeans (Glycine max) are native to Asia, but today this plant is cultivated and con-
sumed world wide. Its nutritional value is good with a high protein content of 40%, includ-
ing all essential amino acids, and an excellent fat profile, as well as a high content of isofla-
vones which are plant estrogens (on average 1.2 mg per gram protein), prebiotic and satiety 
promoting fibers (23%), minerals (particulary calcium and magnesium), vitamins (particu-
larly B1, B2, E and folic acid) (60, 61), and other bioactive components (saponins, trypsin 
inhibitors).  
In recent years, the use of soy-based diets has become very popular for improving lipid 
profiles. The beneficial effects and good tolerability of soy-based products are well known 
(48, 62-64). The lipoprotein lowering effect of soy protein is of particular importance, and 
has been demonstrated in several clinical studies (65-72). The superiority of soy protein re-
garding the capability to reduce blood cholesterol levels compared to animal derived pro-
teins has also been documented (73, 74).  
The lipid lowering effect of soy is assumed to reduce the risk of CHD (75). A meta-
analysis, including 38 clinical trials, has shown that supplementation with soy-based prepa-
rations led to average reductions of total and LDL cholesterols of 9.3% and 12.9 %, respec-
tively (11). 
This is supported by the US Food and Drug Administration (FDA) which in 1999 ap-
proved health claims for products providing a daily dosage of soy protein of at least 25 g, or 
6.25 g/meal (76), and by the Joint Health Claims Initiative (JHCI) which approved similar 
health claims in the UK in 2002.  
Furthermore, soy has also been shown to increase insulin sensitivity (72) and to prevent 
the development of diabetes (77). 
Using soy-based diets is thereby a promising approach to treat elevated blood lipid levels, 
gaining acceptance in the general population. This is supported by a study investigating the 
willingness of people to consume soy foods to lower cholesterol. The findings revealed that 
most of the participants were willing to consume soy preparations as part of their lifestyle 
modification to prevent CVD (14).  
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8  Lipid lowering effect of soy  
The active components in the soybean have not yet been fully elucidated and the mechan-
ism of the lipid-lowering activity of soy protein remains unclear. It is likely that soy protein, 
peptides and isoflavones may all affect lipid metabolism and gene expression (78).         
There are also other soy ingredients such as cotyledon fibers (79, 80) and phospholipids 
(81-84), which reduce serum lipid concentrations. Soy preparations vary not only in their 
content of soy ingredients, they also contain soy protein of varying structure and solubility, 
which may influence efficacy. 
Potential mechanisms of action include the influence of soy on the endocrine system via 
the intestinal absorption of bile acids and dietary cholesterol, and on the hepatic metabolism 
of cholesterol and/or lipoproteins (85). A specific endocrine influence of soy protein on the 
insulin/glucagon ratio is suggested by Anderson (86).  
It is assumed that the cholesterol lowering effect, especially the reduction of LDL, is 
caused by soy peptides, most probably from the 7S -fraction of the globulins (87-89), 
which activate hepatic LDL receptors, and appear to increase the mRNA expression of LDL 
receptors in circulating human monocytes (90). According to Sirtori (1998), soy products 
provide a large amount of protein with high-quality amino acids, which seem to directly up-
regulate LDL receptors by 50% or more (91). Additionally, Kohno documented a significant 
reduction of serum triacylglycerol levels and visceral fat due to dietary intake of  
-conglycinin, which is a component of soy protein isolate (92). 
Isoflavones are compounds that have structures similar to estrogen, with a weaker affinity 
to estrogen receptors. Therefore, it has been postulated that these compounds are partly   
responsible for the lipid lowering effects of soy protein (93). The two major soy isoflavones 
are genistein and daidzein (94). It is well known that mammalian estrogen can modulate 
blood lipid profile, by promoting reduction of LDL-cholesterol and increasing HDL-
cholesterol.  
It is not likely that isoflavones alone will decrease blood lipid levels, however they may 
influence the ability of soy protein to reduce serum lipid concentrations. It is likely that soy 
protein and isoflavones exert synergistic effects. Studies with the single compound could not 
show the same lipid-lowering effect as when both substances were administered together 
(95, 96).  
In soy protein there are also other bioactive components such as saponins, trypsin inhibi-
tors and bioactive peptides which may contribute to the lipid-lowering efficacy of soy, but 
more research is needed in this area. 
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9  Objectives of the thesis 
The primary objective of the studies presented in this thesis was to investigate the choles-
terol lowering effects of different soy based dietary supplements in patients with hypercho-
lesterolemia (Articles 2-5), and in type 2 diabetic subjects (Article 1) with focus on the re-
duction of cardiovascular risk markers. Furthermore, two studies have documented how 
processing influences the lipid lowering effects of soy proteins in humans (Articles 5 & 6). 
 
 
10  Materials and Methods 
The published articles in this thesis represents 10 year of research projects studying the cho-
lesterol lowering properties of soy protein, and of soy protein combined with soy fibre and 
soy phospholipids. Milk protein was used as control, since milk protein is known to have no 
significant lipid lowering properties, and has frequently been used as control in other stu-
dies.  
    When a soy protein based product proven to lower LDL and total cholesterol was made 
into a ready to drink product, which was intended to be a commercially available cholesterol 
lowering beverage, it was UHT treated to sterilize the product for longer shelf life. During 
this UHT process both the soy protein based drink and the milk protein based control beve-
rage significantly increased lipid levels.  
    To study whether it was the denaturation of the protein structure which was responsible 
for the negative effects on blood lipids, we developed a new non-denatured soy protein. 
Substantial time, resources and efforts were used to make this new soy protein out of 1,2 
tones of unprocessed soy flakes, and all processing of the new isolated soy protein had to be 
made in smaller batches of 30-40 kg.  
    In article 1, 25 type 2 diabetic patients from a hospital outpatient clinic were included, 
which had a controlled, double-blind crossover design. For each patient, the diets were iso-
caloric and had similar macronutrient composition up to the start of active and control 
treatment, respectively. The patients were randomly allocated to a 6-week active treatment 
or placebo. The soy supplement provided a daily dosage of 50 g isolated soy protein with a 
high isoflavone content (total isoflavones >165 mg) and 20 g soy cotyledon fiber. The con-
trol contained a daily dosage of 50 g casein and 20 g cellulose. Patients were instructed to 
mix half of their daily supplement in 250 ml water before breakfast and half before the even-
ing meal and to consume as a beverage with the meal. The treatments were separated by a 3-
week wash-out period.  
    Before each study period and during the last week of the 6-week treatment periods, partic-
ipants had to weigh and record their food intake for 2 working days and one weekend day. 
The dietary records were validated by a registered dietitian to estimate the energy intake and 
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composition. Blood samples were taken after overnight fasting before the beginning of the 
study and on the last day of the two intervention periods. The main parameters determined 
in the blood tests were cholesterol (total, LDL, HDL), triglycerides, Apo B100, LDL/HDL-
ratio, and homocystein. Additionally, clinical auscultatory and 24-hour ambulatory blood 
pressure, as well as 24-hour urine samples were collected. Five patients did not complete the 
study. 
In article 2,  143 hypercholesterolemic patients selected from a hospital patient database 
took part in a randomised, controlled, double-blind, parallel-group, single-centre study. The 
hypercholesterolemic patients received yoghurt containing a soy composition based on iso-
lated soy protein with standardized levels of isoflavones, cotyledon soy fibers and soy phos-
pholipids, or a placebo yoghurt based on milk protein and cellulose fiber, over a period of 8 
weeks. All patients were asked to consume one cup two times per day, both morning and 
afternoon, giving a daily dosage of 41.4 g soy protein in the active group and 24.4 g of milk 
protein in the control group. Prior to treatment, the patients followed an open, run-in dietary 
phase of 8 weeks, wherein all participants consumed a cholesterol-lowering diet in order to 
reduce the variability of lipid levels. During the study, all patients were seen in the clinic on 
weeks 0, 2, 4, 6 and 8 for compliance control and blood sampling for lipid measurements. 
The participants then had a final follow-up assessment after another 4 weeks without treat-
ment. All patients were included in the efficacy analysis. 
The study described in article 3 was performed as a prospective single cohort study in-
cluding 53 hypercholesterolemic patients, of which four dropped out. The participants re-
ceived a statin monotherapy for 6 weeks, followed by a combination of statin therapy and a 
soy preparation for 6 weeks and finally statin monotherapy alone for 6 weeks. During treat-
ment with the soy preparation, two sachets containing 45 g of the soy product were to be 
consumed daily, corresponding to an intake of 30 g soy protein. There were six study visits 
where blood samples were drawn, vital signs measured, medication compliance recorded 
and adverse events monitored. Plasma lipid concentrations were measured for cholesterol 
(total, LDL, HDL) and triglycerides. 
Article 4 concerns a randomized, controlled trial, which was performed to investigate the 
lipid lowering effect of two soy-based protein supplements in 117 hypercholesterolemic 
patients from an outpatient hospital clinic. The participants received their nutritional sup-
plements after a run-in period of 2 weeks, after which baseline values were determined. The 
hypercholesterolemic patients were assigned to one of the following 3 study groups: active 
treatment 1, 77.5 g supplement containing 25 g soy protein; active treatment 2, 75.5 g sup-
plement containing 15 g soy protein and 10 g milk protein; control, 76.5 g supplement con-
taining 25 g milk protein. The participants received the preparation in two sachets which 
were dissolved in cold water and which were taken with their morning and evening meals. 
Additional assessments to the baseline examination were made 4, 6, and 8 weeks after base-
 - 19 - 
 
line and involved an evaluation of the general clinical condition of each patient, and where 
blood samples were analyzed to determine serum levels of total cholesterol, LDL and HDL 
cholesterol, triglycerides, apolipoprotein B, and lipoprotein (a). 
The main aim of article 5 was to test an expected cholesterol lowering effects of an ultra 
heat treated (UHT) soy protein based drink. Eighty patients with hypercholesterolemia from 
an outpatient hospital clinic were enrolled in this randomized, controlled, double-blind trial. 
A four-armed study design was chosen, where the participants were assigned to one of the 
following four groups: Active treatment 1 (receiving 1l chocolate-flavored milk containing 
24.4 g soy protein and 30.4 g milk protein daily) or control 1 (receiving 1l chocolate-
flavored milk containing 43.3 g milk protein daily), and active treatment 2 (receiving 0.5l 
chocolate-flavored milk containing 12.2 g soy protein and 15.2 g milk protein daily) or con-
trol 2 (receiving 0.5l chocolate-flavored milk containing 21.7 g milk protein daily). The soy 
protein product and placebo preparation were premixed with low-fat (0.2%) chocolate-
flavored milk and ultra heated (142°C for 4-6 sec) to sterilize the products for long term 
shelf life, and were distributed to the participants. Assessments took place at baseline and 
after 2 and 4 weeks. This involved clinical evaluation and blood sampling to determine se-
rum concentrations of total, LDL and HDL cholesterol. 
In article 6, the cholesterol lowering effect of two different soy proteins was investigated 
in 120 hypercholesterolemic patients from an outpatient hospital clinic in a  randomized, 
double-blind, controlled trial. The patients received their study preparations, containing a 
total of 25 g protein, twice daily. Each dosage was stirred into 250 ml cold water and was 
taken with morning and evening meals. The active test preparation contained an isolated soy 
protein with the protein in its native non-denatured structural form, whereas the reference 
preparation contained a commercially available (conventionally) isolated soy protein which 
are heat treated. Furthermore, a preparation from milk protein, was given to a third group of 
patients in this study. Clinical assessments were performed four times throughout the study 
period. At each visit, the patient’s general medical condition was evaluated and blood sam-
ples were taken.  
Outcome measurements were total cholesterol, LDL and HDL cholesterol. Safety para-
meters such as hemoglobin, glucose and alanine aminotransferase to control liver function 
were determined in the initial and final evaluations. 
     Due to differences of the design in the various studies, different statistical tests were 
used. 
Statistical analysis in article 1 was conducted using the Mann-Whitney test to compare 
the height and age for the groups using active and control treatments at the time of randomi-
zation, and Fisher’s exact test to compare the gender distribution between these groups. 
Analysis of differences within and between treatments were performed using Wilcoxon’s 
matched-pair signed rank test, applied regarding weight, waist, waist-hip ratio, 24-hour 
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blood pressure, fasting values of blood sample measurements and urine tests, whereas meas-
ures of glucose and insulin were evaluated using an analysis of variance with repeated mea-
surements. Wilcoxon’s matched-pair test and Fisher’s exact test were also used in article 3. 
A primary analysis was undertaken in article 2 on a modified intention-to-treat popula-
tion, defined as those patients who received the study treatment for at least two weeks. To 
assess the validity of the results, a secondary analysis was performed, where missing values 
in the intention-to-treat population were substituted according to the last-observation-
carried-forward method. Furthermore, the per-protocol population, consisting of only sub-
jects who completed the study was analyzed. 
Univariate comparisons of the differences between corresponding values versus baseline 
were accomplished by means of analysis of variance in article 4. In the case of significant 
group differences, comparison of pairs were made using Student’s t test. Multivariate analy-
sis of variance for repeated measurements was performed when no significant differences 
between the treatment groups and control were observed. Finally, a new multivariate nonpa-
rametric analysis of covariance for repeated measures was performed. 
The data in article 5 were evaluated according to the full-analysis procedure. In addition 
to variance analysis and the F-test, the t-test for coupled observations was applied. 
In article 6, analysis of variance and the F-test were used to test differences between mean 
changes that were observed in all 3 study groups. If differences occurred, the Student’s t-test 
was used for paired group comparisons. All other data have been evaluated using descriptive 
methods, and have been performed by Realize & Analyse AG, Berlin, Germany. 
All studies were approved by national ethics committees (Article 1: ethics committee of 
Aarhus County, Denmark; Article 2: ethics committee of the Joensuu Health Centre, Joen-
suu, Finland; Article 3: ethics committee in Copenhagen, Denmark; article 4-6: ethics com-
mittee of Humboldt University Medical School (Charité) in Berlin, Germany). 
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11  Results 
11.1   Summaries of the six articles 
Article 1 
 “Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk 
markers in type 2 diabetic subjects” 
K Hermansen, M Søndergaard, LH Høie, M Carstensen, B Brock 
The objective of this controlled, randomized, double-blind crossover study was to inves-
tigate the effects of a dietary supplement containing soy protein, and a high-fixed level of 
isoflavones and cotyledon soy fiber on cardiovascular risk markers, blood glucose and insu-
lin levels in type 2 diabetic patients. Twelve subjects were randomly allocated to a 6-week 
treatment with the active preparation and 8 patients to a 6-week treatment with placebo.  
Subjects were instructed to mix half of their daily supplement in 250 ml water before 
breakfast and half before the evening meal and to consume them as a beverage with a meal.  
Both treatments were separated by a 3-week wash-out period. The percentage mean 
treatment difference between soy protein and control showed significantly lower mean val-
ues after soy protein treatment for LDL cholesterol (10 ± 15%, P < 0.05), LDL/HDL ratio 
(12 ± 18%, P < 0.05), apolipoprotein (apo) B100 (30 ± 38%, P < 0.01), triglycerides (22 ± 
10%, P < 0.05) and homocystein (14 ± 21%, P < 0.01). Total cholesterol was reduced in the 
soy protein group, however not significantly (8 ± 15%, P < 0.08) from the control  group. 
No changes could be found in HDL cholesterol, apo B100/apo A1 ratio, plasminogen activa-
tor inhibitor1, factor VIIc, von Willebrand factor, fibrinogen, lipoprotein(a), glucose, HbA1c, 
or 24-hour blood pressure when using soy protein. In conclusion, the active soy based dieta-
ry supplementation led to beneficial effects regarding reduction of cardiovascular risk mark-
ers in type 2 diabetic subjects. 
Published in Diabetes Care 2001; 24 (2): 228-233 
 
Article 2 
“Isolated soy protein with standardized levels of isoflavones, cotyledon soy fibers and soy 
phospholipids improves plasma lipids in hypercholesterolemia: a double-blind, placebo-
controlled trial of a yoghurt formulation” 
P Puska, V Korpelainen, LH Høie, E Skovlund, KT Smerud 
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In this randomized, double-blind, controlled study, 143 subjects with hypercholesterole-
mia were enrolled and randomly assigned to the soy group (n=69) or the control group 
(n=74).  
Over a period of 8 weeks, patients in the soy group received yoghurt containing a soy 
composition, based on isolated soy protein with standardized levels of isoflavones, cotyle-
don soy fibers and soy phospholipids. All patients were asked to take one cup twice a day, in 
the morning and afternoon. Prior to treatment, an open, run-in dietary phase of 8 weeks was 
followed, wherein all subjects consumed a cholesterol-lowering diet in order to reduce the 
variability of their lipid levels.  
Efficacy parameters were determined five times during the intervention period and 4 
weeks later. Significant differences in lipid-lowering effect was found in favor of the active 
soy intervention group compared with the control group with respect to total cholesterol 
(estimated mean difference 0.40 mmol/l; P<0.001), LDL-cholesterol (0.39 mmol/l; 
P<0.001), non-HDL cholesterol (0.40 mmol/l; P<0.001) and total/HDL-cholesterol ratio 
(0.23; P=0.005). There was no difference regarding effects on HDL-cholesterol, triacylgly-
cerols or homocystein. It was found that the lipid-lowering effect occurred within the first 
two weeks and was not caused by weight loss. Gastrointestinal symptoms caused a signifi-
cantly higher drop-out rate (fourteen v. three subjects) in the soy group. However, the safety 
profile for active soy was similar to the placebo group. 
Published in British Journal of Nutrition 2004; 91: 393-401 
 
Article 3 
“Treatment with Abacor®, a soy-based dietary supplement, further reduces plasma 
concentrations of total and low-density lipoprotein cholesterol in statin-treated 
hypercholesterolaemic patients” 
P Clausen, J Lindhardsen, LH Høie, S Stender 
This study was performed to test whether a soy-based dietary supplement reduces choles-
terol concentrations when administered to statin treated hypercholesterolemic patients. A 
total of 53 subjects with a plasma LDL-cholesterol concentration of >3.0mmol/l at baseline 
despite statin treatment were enrolled in this open label single center cohort study with six 
study visits. The participants received statin monotherapy for 6 weeks, statin and active 
treatment for 6 weeks and finally statin monotherapy for 6 weeks. During treatment with the 
active supplement two sachets of the soy product containing each 45 g were consumed dai-
ly, corresponding to an intake of 30 g soy protein per day. In total, 49 patients completed the 
study. It was found that plasma concentration of total cholesterol and LDL cholesterol were 
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significantly reduced at visit 5 (6 weeks of combination treatment) compared to the choles-
terol mean values both after 6 weeks of statin monotherapy at visit 3 and of visit 6: 5.5 ± 0.1 
vs. 5.9 ± 0.1mmol/l (P<0.0004) and 3.3 ± 0.1 vs. 3.6 ± 0.1mmol/l (P<0.0006). It was con-
cluded that the soy-based dietary supplement further significantly reduces total cholesterol, 
mainly by reducing LDL cholesterol when given in combination with statins in hypercho-
lersterolemic patients. 
Published in Innovative Food Science and Emerging Technologies 2004; 5: 377-383 
 
Article 4 
“Lipid-lowering effect of 2 dosages of a soy protein supplement in hypercholesterolemia” 
LH Høie, HJ Graubaum, A Harde, J Gruenwald, KD Wernecke 
An 8-week randomized, controlled trial was performed to investigate the lipid lowering ef-
fect of a soy-based protein supplement in 117 patients. The participants were allocated to 
three different groups, one receiving 15 g/d soy protein, the second 25 g/d soy protein and 
the third control group with 25 g/d milk protein. The general clinical condition of each par-
ticipant was determined at baseline, and after 4, 6 and 8 weeks. In the soy groups, LDL cho-
lesterol levels decreased significantly by 1.1% and 5.9% respectively, whereas levels in-
creased by 3.6% in the control group. Similar changes could be found for total serum cho-
lesterol and apolipoprotein B. HDL cholesterol, triglycerides, homocysteine, folic acid, and 
vitamin B12 levels did not change significantly compared with baseline values in any study 
group. This study demonstrated that soy protein supplementation reduced serum cholesterol 
levels, and that 25 g soy protein was more effective compared to an intake of 15 g/d. 
Published in Advances in Therapy 2005; 22 (2): 175-186 
 
Article 5 
“Ultra heat treatment destroys cholesterol-lowering effect of soy protein” 
LH Høie, Å Sjoholm, M Guldstrand, HJF Zunft, W Lueder, HJ Graubaum, J Gruenwald 
To investigate the dosage-dependent response on serum cholesterol after consuming an 
ultra-heat-treated soy protein preparation, a randomized, controlled, double-blind trial was 
conducted. A total of eighty subjects with hypercholesterolemia were assigned to one of the 
following four groups receiving 12.5 g or 25 g soy protein (active treatment) or casein (“pla-
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cebo”) daily over a period of 4 weeks. At baseline and after 2 and 4 weeks blood samples 
were taken to determine serum concentrations of total, LDL and HDL cholesterol.  
It was found that LDL cholesterol concentrations were significantly increased compared 
to baseline in all study groups. The magnitude of this increase (17-21%) was similar in all 
active and control study groups, whether the UHT treated proteins beverages were based on 
soy or milk protein. The soy protein supplements previously shown to significantly reduce 
serum cholesterol, significantly increased cholesterol levels after ultra heat treatment in this 
study. 
Published in International Journal of Food Sciences and Nutrition 2006; 57 (7/8): 512-519 
 
Article 6 
“Cholesterol-lowering effects of a new isolated soy protein with high levels of non-denatured 
protein in hypercholesterolemic patients” 
LH Høie, M Guldstrand, Å Sjoholm, HJ Graubaum, J Gruenwald, HJF Zunft, W Lueder 
The aim of this prospective, randomized, double-blind, controlled trial was to compare 
the effects of a new isolated soy protein in which the protein structure was kept in its native, 
non-denatured form (verum 1) versus a conventional isolated soy protein (verum 2) and 
milk protein (control) on plasma cholesterol levels. Over a period of 8 weeks, 120 patients 
were given verum 1, verum 2 or control containing a daily dosage of 25 g protein. Com-
pared to control, total cholesterol levels were significantly reduced by 10.7% in the verum 1 
group (P<0.001), and by 5.8% in the verum group 2 (P=0.008). The difference between the 
two verum groups lowering total cholesterol was significant (P=0.008). LDL cholesterol 
levels were significantly reduced with the non-denatured isolated soy protein in the verum 1 
group, by 9.4% (P=0.002), and by 4.9% in the verum 2 group (P=0.107). The difference 
between the verum groups in lowering LDL cholesterol was significant (P=0.05). The lipid-
lowering effects of the new isolated soy protein with its protein and peptide structures intact 
was approximately twice that of a conventional isolated soy protein. 
Published in Advances in Therapy 2007; 24 (2): 439-447 
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11.2 Summary of the results. 
 
Recently, we have published a paper (not included in the thesis) which summarizes the lipid 
lowering effects in our soy protein research, and how denatured protein causes an altered 
biological response (97). The enclosed figure summarizes the cholesterol lowering effects 
presented in the various clinical studies we have published. 
 
Ultra heat treatment not only ruins the lipid lowering properties of soy protein, but signif-
icantly increased cholesterol levels, thereby being potentially atherogenic. The same was 
found for the milk protein based control drink which was UHT treated. Hence, for the first 
time to our knowledge a clear parallel with regards to the processing of proteins has been 
found, compared to the processing of polyunsaturated fatty acids into trans fatty acids, 
where also an increased risk of CVD has been documented. 
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12  Discussion 
12.1    Design 
Studies described in articles 1, 2, 4, 5 and 6 in this thesis, have a randomized, double-
blind, controlled design in type 2 diabetic subjects (article 1) and in hypercholesterolemic 
patients (articles 2, 4, 5, 6). Furthermore, study 1 was performed as a crossover study. Ar-
ticle 3 presents an open label single center cohort study. 
 
12.2   Weaknesses, strengths, arguments 
In article 1, only 25 patients were included into the study, which is a small number for 
such an investigation. However, the cross over design strengthens the results. Otherwise the 
study designs and population sizes used in the clinical trials of this thesis were adequate. 
Five of the six studies were performed using a randomized, double-blind, controlled study 
design, which is regarded as the best standard for clinical trials. All studies were approved 
by ethics committees. Only the study reported in article 3 was conducted as an open label, 
single-center, cohort study without a control group, which can be regarded as a weakness for 
this study. However, the design of the study with an initial 6-week period of unchanged sta-
tin medication after dietary instructions should reduce a potential “cholesterol-lowering ef-
fect” by the participants’ awareness of and possible lifestyle changes due to the study partic-
ipation itself.   
  Dietary studies are normally influenced by several factors, such as seasonal or dietary 
adaptation and inaccurate self-reporting. In most of the studies the patients got dietary ad-
vice from a registered dietitian. Nevertheless, it cannot be ruled out that various individual 
dietary behaviors of the subjects had an impact on the results of the studies presented. 
Another approach was dietary food control by keeping a food diary. Unfortunately, this was 
considered to be inappropriate in the study reported in article 2. The study was intended to 
diminish any effect on normal life. Keeping a food diary was assumed to introduce an ad-
verse effect on normal life of these subjects compared to frequent visits to the study nurse. A 
weakness in this study can also be seen from the fact that the two products compared, were 
not completely identical in fat content as there were manufacturing obstacles to maintain 
blinding in terms of appearance, smell and taste if the fat content was kept identical. It was 
assumed that this difference in fat content could explain some of the differences, which 
needs careful consideration in future studies. It is also questionable as to whether the control 
was actually an inactive substance, since the control group also showed a smaller reduction 
in lipids. 
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12.3  Patients 
Article 1 investigates the effects of a soy-based dietary supplement on lipid levels and 
cardiovascular risk markers in type 2 diabetic subjects with serum lipid abnormalities. In all 
other studies, patients with hypercholesterolemia were studied. Subjects were selected from 
the patient database of different hospital outpatient clinics.  
 
12.4   Efficacy 
It has been documented that soy protein lowers elevated blood lipids in hypercholestero-
lemic subjects (11).  
    Dietary studies are influenced by a number of factors (98). Seasonal or dietary adaptation, 
as well as inaccuracy of self-reporting of dietary data may complicate the analyses. Fur-
thermore, study design also varies considerably, with a treatment period of 5 to 24 weeks 
(67, 68, 90, 99) and soy protein intake of 17 to 125 g daily (72). Furthemore, various 
processing techniques may influence results. Subsequently, published results obtained from 
clinical studies in recent years have been inconsistent (63, 67, 68, 69, 71).  
The study described in article 1 shows that the intake of a soy-based preparation signifi-
cantly reduced LDL cholesterol levels, LDL/HDL ratio, apolipoprotein and triglycerides in 
diabetic patients. HDL cholesterol, however, remained unchanged. These findings are in 
accordance with the results in a meta-analysis with nondiabetic subjects performed by An-
derson (11). Reduction of blood glucose and insulin levels were modest, which also have 
been found in other studies in diabetic patients (100, 101). The results document beneficial 
effects of an intervention with a soy-based preparation in reducing cardiovascular risk mark-
ers in type 2 diabetic subjects. The risk for coronary heart disease (CHD) is two to three 
times higher among adults with type 2 diabetes than in the general population (102, 103), 
and with a four to six times greater cardiovascular mortality (104). Serum lipid abnormali-
ties in type 2 diabetes are normally characterized by decreased HDL cholesterol and hyper-
triglyceridemia, whereas total cholesterol and LDL cholesterol levels are similar to those in 
non-diabetic subjects.A rapid onset of the cholesterol-lowering effect was documented in 
article 2. Approximately half the lipid-lowering effect after 8 weeks treatment was observed 
after the first week.  
It was demonstrated in article 3 that statin treated patients with moderate hypercholeste-
rolemia significantly further reduced LDL- and total cholesterol, when given a soy-based 
preparation.  This is surprising since the cholesterol-lowering effect of soy shown in pre-
vious studies has been found to positively correlate with baseline cholesterol concentration 
(11). The cholesterol-lowering effect of soy is also associated with gender. The results of 
article 3 showed that the lipid lowering effect was more pronounced in men, whereas no 
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significant effect was seen in women. This indicates that soy given to hypercholesterolemic 
patients treated with statins may be beneficial to men, but not to women.   
The indication of a possible gender difference in response to soy may reflect the impor-
tance of the isoflavone content. Isoflavones are natural plant estrogens from soy which 
weakly bind to estrogen receptors and may thereby initiate a cholesterol-lowering effect 
similar to that of estradiol found in other studies (105). However, the number of women 
participating in the study presented in article 3 was small and a possible gender difference 
with regards to the plasma cholesterol lowering effect of soy needs further investigation.  
Results in article 4 demonstrate that the lipid-lowering effect is influenced by the amount 
of soy protein intake daily. The reduction of lipids resulting from a daily intake of 25 g soy 
protein was documented to be larger than that of a daily intake of 15 g. 
LDL cholesterol, which is a major risk factor for cardiovascular disease, was significantly 
reduced in all of the studies of this thesis, except when the soy protein was UHT-treated 
(article 5), when LDL and total cholesterol significantly increased. 
There are different alternatives of processing soy-beans, and most of the manufacturing 
steps are accompanied by heat treatments (106), which alter the protein structure (107). An 
overview of the literature on the effects of temperature on food proteins and its implications 
on functional properties is given by Kilara and Sharkasi (108). 
The conventional ISP achieved only moderate lipid lowering effects in a previous clinical 
study (70), and in a proteomic investigation it was shown to be highly fragmented in its pro-
tein constituents (109).  
In conventional processing of proteins the structure may be altered, which may influence 
biological effects (110). Soy protein previously shown to reduce serum cholesterol had no 
such lipid-lowering effect after ultra-high heat treatment, when both total and LDL-
cholesterol levels very surprisingly significantly increased, as documented in article 5. In a 
follow-up study using the same soy protein without the preceding ultra heat treatment, total 
cholesterol and LDL cholesterol were significantly reduced during a 4-week treatment pe-
riod (article 5). 
It is likely that the significant increase in blood lipid levels found after ultra heating of the 
soy protein is due to heat-induced denaturating of the protein which changes the constituents 
of the soy protein responsible for the serum cholesterol reduction, including soy peptides 
from 7S globulins.  
It took considerable time and effort to develop the new isolated soy protein (ISP) for the 
study presented in article 6, and the new ISP could only be manufactured in approximately 
30 kg batches from 1.2 tonnes of defatted soybean flakes. Microbiological growth was con-
trolled in the new ISP by freeze drying down to a very low moisture content of approximate-
ly 5%. In the hypercholesterolemic patients participating in this study the new ISP, in which 
the major part of the protein was in its non-denatured form with its native protein and pep-
 - 29 - 
 
tide structures intact, was compared with a commercially available ISP. The reduction of 
total and LDL cholesterol was significantly more pronounced with the new ISP, which was 
twice as effective in lowering lipids when directly compared to the commercially available 
ISP.   
Wright and Boulter (111) detected a thermal transition ascribed to 11S globulin (glyci-
nin), and it was found that the 7S form of glycinin is especially sensitive to heating, with 
denaturation occuring at a lower temperature (about 60°C) than the 11S globular form (112, 
113).  
Recent investigations by Amigo-Benavent (114) show that the quality, antigenicity and 
antioxidant activity of soy protein can be affected by the intensity of thermal processing. An 
immunoblotting assay revealed modifications in the antigenic response of soy foods, sug-
gesting that the processing had altered the structure of soy allergens.  
Coward (115) suggests that chemical modification of isoflavones in soyfoods during 
cooking and processing may influence the bioavailability and pharmacokinetic properties of 
soy. Of importance is the composition of the isoflavone glucoside conjugates which can 
alter rates of absorption and metabolism. -glucosides can be malonylated, acetylated or 
unesterified in the 6´´-OH position.  
It has been demonstrated that treatment of soy flour or soy protein concentrate with tem-
peratures of up to 190°C does not change the total isoflavone content (115, 116). However, 
the portion of the 6´´-O-malonyl derivates decreases due to decarboxylation, which may 
have an important effect on bioavailability.  
When soy protein denatures, the globular structure opens, resulting in long-chain pro-
teins, which can form insoluble aggregates (107, 117). Apparently, a higher degree of ag-
gregation reduces the amount of bioactive soy peptides from digestion that can be absorbed 
through the intestines.  
More research is needed to investigate the impact of processing of soy protein, especially 
with regards to the impact of UHT in increasing lipids, which again may increase the risk 
for cardiovascular disease.  
Increased cardiovascular risk is also associated with trans fatty acids (TFA). Most trans 
fats consumed today are industrially created by partially hydrogenating unsaturated fats at 
high temperatures, making them more saturated and transforming cis-double bonds to trans-
double bonds. Consumption of trans fats is known to increase the risk of coronary heart dis-
ease by raising the levels of LDL cholesterol and lowering HDL levels (118, 119, 120). Also 
an increase of plasma triacylglycerol levels (121) and a relationship between TFA and sys-
temic inflammation, endothelial dysfunction (122, 123) and increased risk of type 2 diabetes 
has been observed (124).  
In addition, TFA derived from industrially produced sources have specific HDL choles-
terol-lowering properties (125). Another study revealed that replacement of dietary unsatu-
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rated fatty acids by TFA not only decreased HDL levels in healthy men and women, but also 
impaired flow-mediated vasodilatation of the brachial artery, which is a risk marker for co-
ronary heart disease (126, 127).  
Current dietary recommendations to keep TFA intake as low as possible and the growing 
awareness of those recommendations by consumers and food regulatory agencies have been 
major driving forces for the edible oil industry and food manufacturers to develop alterna-
tive fats and oils with nutritionally improved fatty acid compositions (128, 129, 130).  
In 2006 the U.S. Food and Drug Administration (FDA) issued a final rule that requires 
the declaration of the amount of TFA present in foods, including dietary supplements, on the 
nutrition label. For the purpose of nutrition labeling, TFA are defined as the sum of all unsa-
turated fatty acids that contain one or more isolated (i.e. non-conjugated) double bonds in a 
trans configuration. It is assumed, that this approach will lead to the prevention of 600 to 
1200 cases of coronary heart disease (CHD) and 240-480 deaths each year, saving US$ 900 
mill. to US$ 1.8bn in yearly medical costs (128).  
In Denmark, legislation virtually eliminated the intake of industrially produced trans fatty 
acids (IP-TFA), by banning any food with an IP-TFA content > 2% of total fat within a few 
years (129).  
Oilseeds with modified fatty acid composition, (e.g. enhancement of the content of long-
chain omega-3 fatty acids or conjugated linoleic acid) have been developed to increase the 
delivery of these fatty acids directly into the food supply or indirectly as use for feed ingre-
dients for livestock. New processing technologies have been developed to create dietary fats 
and oils with specific physiologic functions related to risk factors for CVD (130). 
Changing the structure of protein may alter its biological effects, as we have documented 
in Article 5. New processing technologies have been developed to create dietary proteins 
with specific physiologic functions. Investigations have been performed, e.g. by Kwok 
(131), who carried out optimization of the thermal processes for soy milk to obtain a mini-
mum degradation of sensory and nutritional qualities. However, no one has to our know-
ledge previousely documented that UHT treatment of proteins may alter the biological ef-
fects in humans by significantly increasing cholesterol levels, thereby possibly increasing 
the risk for CVD. 
 
12.5   Safety 
Consumer safety has the highest priority also when it comes to dietary interventions. 
Suitable parameters to assess safety of a product are drop-out rates and questionnaires do-
cumenting side effects and well-being. 
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Drop-out rates were very low in articles 1 and 3-5 of this thesis. In most cases, the con-
sumption of the soy-based preparations was very well tolerated, with slight temporary ga-
strointestinal discomfort being the most common side effect.  
In article 2, a considerable drop-out-rate was reported. Fourteen subjects (20.3%) from 
the active soy group, and three (4.1%) from the control group dropped out of the study dur-
ing the intervention period. The high fiber intake may partly explain gastrointestinal symp-
toms reported by these subjects. A lower dosage taken for a longer term may be as effective, 
but this has to be confirmed in further dose-response studies. 
A higher number of drop-outs was also reported in article 6. Of the 120 patients included, 
88 completed the study, the other 32 (26.7%) withdrew prematurely, mainly because they 
did not like the taste of the study preparation. Since there was a high drop-out-rate in the 
verum groups taking soy (12 and 8) as well as in the placebo group (12), it is likely that the 
intolerance was not caused by the soy ingredients. 
Safety was assessed by measurements of a number of risk factors and biochemical para-
meters, which were determined at the initial and final evaluation. In article 2 for example, 
hematology and biochemistry blood tests were taken (alanine aminotransferase, aspartate 
aminotransferase, creatinine, glucose and uric acid), as well as a physical examination in-
cluding blood pressure and heart rate. No significant changes in any of the hematological or 
biochemical laboratory variables were found. The same results were reported in the other  
articles. 
 
 
13  Conclusions 
    This thesis comprises the description and results of six clinical studies investigating the 
cholesterol lowering effects of soy products and soy protein based diets. In article 1, the ef-
fects of a soy-based dietary supplement was investigated on lipid levels and cardiovascular 
risk markers in type 2 diabetic subjects with serum lipid abnormalities. In the other studies, 
patients with hypercholesterolemia were examined. The studies were performed at universi-
ty hospitals in the Nordic countries and Germany, with a study population ranging from 25 
to 143 patients. The study period, which was often accompanied by wash-out periods before 
starting a particular treatment or between different treatments, varied from 4 to 8 weeks.  
The results of the study described in article 1, investigating the effects of a soy-based die-
tary supplement on lipid levels and cardiovascular markers in type 2 diabetic subjects,   
demonstrated that consumption of the soy-based formulation reduced cholesterol and other 
risk factors for CVD, which was also seen in individuals with near-normal lipid values. The 
lipid-lowering effects was observed in article 2 after 1-2 weeks of intervention, and was not 
caused by weight loss. This rapid onset of effect may be of particular benefit to those who 
need motivation during the early phases of treatment, and who are not able to comply with 
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lifestyle modification programs. Article 3 showed that treatment with a soy-based dietary 
supplement significantly further reduced plasma concentrations of total and LDL cholesterol 
in statin treated hypercholesterolaemic patients. Therefore, a soy-based diet represents an 
attractive alternative to increasing the dosage of statins. The results of study 4 also demon-
strated that soy protein supplementation reduced serum cholesterol levels, and that 25 g of 
soy protein was more effective than 15 g per day.  
Article 5 describes the cholesterol-lowering effects of soy proteins after ultra heat treat-
ment. A soy protein supplement, previously shown to significantly reduce serum cholesterol, 
significantly increased LDL and total cholesterol after UHT treatment, which is likely 
caused by changes in the protein structure. This was supported by the results in article 6, 
where the cholesterol-lowering effect of a new isolated soy protein, with high levels of non-
denaturated protein, was compared to a conventional isolated soy protein in hypercholeste-
rolemic patients. The lipid-lowering effects of the new isolated soy protein, with its protein 
and peptide structures intact, was approximately twice as large when compared to the con-
ventional isolated soy protein.  All soy products used in the clinical trials were found to be 
well tolerated and safe, causing only minor side effects. 
These results may have important implications when it comes to the health effects and 
safety of proteins based foods and ready to drink products in the way the food and beverage 
companies process proteins. All UHT drinks, which have been ultra heated for long shelf 
life, whether containing soy protein, milk protein or other proteins, may be atherogenic and 
increase the risk for cardiovascular disease. The finding that a non-denaturated soy protein 
was twice as effective in lowering lipid levels compared to a conventional soy protein which 
is heat treated with some denaturation, further document these results.  
Conventional soy proteins will have been heat treated during their processing by most 
producers, whereby some of the cholesterol lowering properties is lost. Some of the major 
soy producing companies use ethanol in their processing, which denatures protein, and as 
such ethanol processing may also be atherogenic.  
There is limited literature with regards to processing/heating of protein based foods and 
drinks and changes in their biological and functional properties. More research is needed to 
document potential side-effects, efficacy and safety with regards to the processing of dietary 
proteins, and the implications for human health. 
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The objective was to study whether a yoghurt containing isolated soya protein with standardised levels of isoﬂavones, cotyledon soya ﬁbres
and soya phospholipids is more effective in lowering total and LDL-cholesterol than a placebo. One hundred and forty-three subjects were
randomised to the soya group (n 69) or to the placebo (n 74). The mean baseline levels were 7·6 and 5·1mmol/l for total and LDL-choles-
terol, respectively. Fasting serum lipoproteins were assessed ﬁve times during the 8-week intervention period, and 4 weeks thereafter. The
results were analysed by a mixed model for unbalanced repeated measurements. During the intervention, there were highly signiﬁcant
differences in lipid-lowering effect in favour of the active soya intervention group compared with the control group. The signiﬁcant differ-
ences were for total cholesterol (estimated mean difference 0·40mmol/l; P,0·001), LDL-cholesterol (0·39mmol/l; P,0·001), non-HDL-
cholesterol (0·40mmol/l; P,0·001) and for the total:HDL-cholesterol ratio (0·23; P¼0·005). There was no difference in the effects on
HDL-cholesterol, triacylglycerols or homocysteine. The lipid-lowering effect occurred within 1–2 weeks of intervention, and was not
due to weight loss. The safety proﬁle for active soya was similar to the placebo group, except for gastrointestinal symptoms, which
caused a signiﬁcantly higher dropout rate (fourteen v. three subjects) among the subjects taking active soya.
Soya protein: Fibre: Isoﬂavones: Phospholipids: Hypercholesterolaemia
It is well established through epidemiological research that
hypercholesterolaemia is among the major causes for CHD
and that changes in diet may inﬂuence this and other risk
factors for such disease (Pietinen et al. 1996; Grundy,
2000; Stamler et al. 2000; Vartiainen et al. 1994). Several
large, prospective intervention studies using statins have
further demonstrated that reducing the cholesterol level
also reduces the risk of cardiovascular morbidity and mor-
tality (The Scandinavian Simvastatin Survival Study
Group, 1994; Shepherd et al. 1995; The Long Term
Intervention with Pravastatin in Ischemic Disease
(LIPID) Study Group, 1998; Heart Protection Study
Collaborative Group, 2002).
A public health approach to primary prevention of CHD
is to call for lifestyle changes; for example, a reduced
intake of cholesterol and saturated fat, exercising, weight
control and smoking cessation (Anonymous, 2002). There
is still some debate whether or when drug intervention is
indicated for primary prevention, partly because of cost
considerations and partly because of concerns over the
safety of lipid-lowering drugs. Reports from the UK indi-
cate that patient and primary-care compliance with public
recommendations are not followed entirely (Anonymous,
1998; Monkman, 2000; Primatesta & Poulter, 2000). As
with other patient groups, hypercholesterolaemic patients
also may be incapable of modifying their lifestyle signiﬁ-
cantly, they may be unable to comply with statin treatment
(Avorn et al. 1998), or they may simply not want interven-
tion with drugs. Various dietary supplements and func-
tional foods have thus recently been introduced as
alternatives to pharmaceuticals. In our view, before being
acknowledged in clinical practice, such products should
have their efﬁcacy and tolerability documented by well-
designed, prospective, randomised, double-blind and rigor-
ously monitored clinical trials.
The lipid-lowering efﬁcacy of soya protein is supported
by the fact that the US Food and Drug Administration
(1999) has approved a health claim for products giving
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a daily dose of soya protein of at least 25 g. A pertaining
problem with clinical studies of soya proteins has been
that the variability of products has been huge, as each
soya-based product may have different soya components,
either isolated or not. In particular, using alcohol extrac-
tions for isolating the soya protein will also remove
isoﬂavones, components that due to their oestrogenic or
anti-oestrogenic effects very well may affect serum lipid
levels. A recent meta-analysis (Anderson et al. 1995)
reviewed several controlled studies and concluded that
the dietary substitution of soya protein for animal protein
might decrease the risk of cardiovascular disease by
decreasing serum cholesterol, LDL-cholesterol and triacyl-
glycerol concentrations, and by slightly increasing serum
HDL-cholesterol levels.
The active components of soya have not yet been fully
elucidated. It has been suggested (Anderson, 2003) that
soya protein, peptides and isoﬂavones may work together
to produce effects on lipid metabolism and gene
expression. Several potential mechanisms of action have
been suggested including an inﬂuence on the endocrine
system, on the intestinal absorption of bile acids and diet-
ary cholesterol, or on the hepatic metabolism of cholesterol
and/or lipoproteins (Potter, 1998) and a more speciﬁc
endocrine inﬂuence of soya protein on the insulin:glucagon
ratios (Anderson et al. 1999). Soya peptides, most probably
from the 7S a-fraction of the globulins (Lovati et al. 2000),
are supposed to activate hepatic LDL receptors, and they
appear to increase the mRNA expression of LDL receptors
in circulating human monocytes (Baum et al. 1998).
Isoﬂavones have structures similar to mammalian oestro-
gens and they are capable of binding to oestrogen receptors.
Depending on the hormonal status of the individual they
seem to exhibit either oestrogenic or anti-oestrogenic
effects. Therefore it has been postulated that premenopau-
sally isoﬂavones may act anti-oestrogenic, whereas they
could act post-menopausally as oestrogen receptor agonists.
It is known that mammalian oestrogens can modulate the
blood lipid proﬁle, promoting decreases in LDL-cholesterol
and increases in HDL-cholesterol. Oestradiol also shows
potent cardioprotective effects on blood vessels (Potter,
1998). Isoﬂavones alone will not decrease blood lipid
levels as described, but they inﬂuence the ability of soya
protein preparations to reduce serum lipid concentrations.
Anderson et al. (1999) proposed several other mechan-
isms by which soya ﬁbres could inﬂuence fasting and post-
prandial serum lipid protein concentrations. Due to the
alteration of gastric emptying and intestinal transit time,
dietary ﬁbres could alter the kinetics of lipid absorption.
Dietary ﬁbre may decrease lipid absorption by modifying
pancreatic secretion, the variation of intestinal motility,
or by changing transport barriers such as the unstirred
layer. Dietary ﬁbre may affect the secretion rates of insulin
or other pancreatic or intestinal hormones, which will
change lipid and lipoprotein synthesis and secretion rates.
Another suggested mechanism is that the soluble ﬁbre of
soya beans is fermented in the colon and generates
SCFA such as acetate, butyrate or propionate, which inhibit
hepatic lipid synthesis (Nishina & Freedland, 1990).
Phospholipids from soya beans may protect against
atherosclerosis development (Navder et al. 2000). The
most obvious action of unsaturated lecithin is the protec-
tion of LDL against oxidation and peroxidation. Oxidised
LDL are involved in the development of atherosclerotic
lesions. Peroxidation of LDL-lipids could damage apo
B-100, the surface protein of LDL and VLDL. This may
increase atherogenicity, because normal catabolism
through the regulated LDL receptor pathway is blocked.
This results in an enhanced cholesterol uptake via an un-
regulated scavenger pathway, which leads to the choles-
terol overloading of macrophages and the development of
foam cells, a key component of atherosclerotic plaques.
One major mechanism of phospholipids or soyabean
lecithin is the activation of reverse cholesterol transport.
This includes the activation of lecithin-cholesterol-acetyl-
transferase, increased cholesterol uptake by HDL and
leads to an increased biliary excretion of cholesterol (Ros-
seneu et al. 1979; Ishida et al. 1988; Hsia et al. 1996; Poli-
chetti et al. 1996, 2000; LeBlanc et al. 1998).
Abacorw is a new product based on isolated soya protein
and cotyledon soya ﬁbres containing standardised levels of
isoﬂavones as well as soya phospholipids. Initial studies in
subjects with mild-to-moderate hypercholesterolaemia
have demonstrated that this product is efﬁcient in lowering
cholesterol (Puska et al. 2002; Tonstad et al. 2002). These
early results were obtained by administering the soya pro-
duct in a powder formulation to be mixed with water
before intake. The aim of the present study was to demon-
strate similar lipid-lowering effects with this active soya
product when administered in a yoghurt formulation.
Methods
Subjects
Subjects were screened from the patient database of the
Joensuu Health Centre area in North Karelia, Finland.
Eligible subjects had to meet selection criteria including:
written informed consent; total serum cholesterol concen-
tration of 6·7–9·9mmol/l; serum triacylglycerols of
,4·5mmol/l; age 18–75 years for men and 45–70 years
for post-menopausal women (at least 6 months with no
vaginal bleeding after menopause). Subjects were to have
no signiﬁcant signs of cardiovascular, renal, hepatic, endo-
crine or gastrointestinal disease; no familial hypercholes-
terolaemia; no type I or II diabetes mellitus treated with
insulin; no past or concomitant use of statins, n-3-fatty
acids or other lipid-lowering drugs (including any choles-
terol-lowering functional foods) during the last 8 weeks
before randomisation. They were to have had no hormone
replacement therapy within the past 6 months; have no
drug or alcohol dependency; no eating disorder; and no
plans to lose weight during the study.
Study design and laboratory analyses
Subjects with hypercholesterolaemia were informed about
the study and invited to participate. After having given
their informed consent to participate in the study, the sub-
jects were followed for 8 weeks in an open, run-in dietary
phase. During this time all subjects were asked to consume
a cholesterol-lowering diet in order to reduce the variabil-
ity of their baseline lipid values as recommended
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by The Swedish Medical Product Agency and the Norwe-
gian Medicines Control Agency (1996). Their guidance is
similar to the American Heart Association step I choles-
terol-lowering diet (Anonymous, 2002) which recommends
that the energy intake from fat should not exceed 30% of
the total energy. After a baseline medical assessment, sub-
jects who met the selection criteria were randomised to one
of the two study groups. They were advised to take one
yoghurt serving twice daily for the next 8 weeks as part
of their normal morning and evening meal. It was
attempted to keep the energy intake as constant as possible
by advising the subjects to reduce their morning and eve-
ning meal with approximately the same amount of
energy as they received through the study products. All
subjects were seen in the clinic at week 0, 2, 4, 6 and 8
for compliance control (deemed by counting returned and
unused containers) and blood sampling for lipid measure-
ments. The subjects then had a ﬁnal follow-up assessment
after another 4 weeks without administration of any study
treatment.
Fasting blood samples were taken, after 5min supine
rest, during each visit for measurement of the efﬁcacy
lipid variables. Total cholesterol, HDL-cholesterol and tri-
acylglycerols were analysed for every visit, whereas homo-
cysteine was measured at baseline and at the end of
therapy. Blood tests for safety haematology and biochem-
istry (alanine aminotransferase, aspartate aminotransferase,
creatinine, glucose and uric acid) as well as a brief physical
examination including the control of blood pressure and
heart rate were taken only at baseline and at the end of
treatment. All lipids were analysed at the Department of
Biochemistry at the National Public Health Institute,
Helsinki, Finland. The concentrations of LDL-cholesterol
were calculated according to the Friedewald et al. (1972)
method. As soya products contain high levels of the isoﬂa-
vones genistein and daidzein (Adlercreutz, 1998), plasma
concentrations were measured by ﬂuoroimmunoassay
(Wang et al. 2000) after 8 weeks treatment as an objective
measure of treatment compliance. Weight was measured at
each visit, but there was no detailed diary recording in
order to control energy intake. Tolerability was assessed
by recording spontaneously reported adverse events, as
well as by actively asking an open, non-leading question
to the patient during every visit whether they had experi-
enced any undesirable medical event since their last
clinic visit.
Study product
The subjects were asked to take one cup per twice-a-day
serving, both morning and afternoon, giving a daily dose
of soya protein of 41·4 g for the Abacorw group. The
active Abacorw yoghurt (the active soya treatment) was
manufactured by Protein Technology International Inc., St
Louis, MO, USA (soya protein and ﬁbres) and Lucas
Meyer, Hamburg, Germany (soya lecithin), whereas the
placebo yoghurt was the commercially available product
‘Lett Yoghurt Naturell’, manufactured by Tine Sør,
Kristiansand, Norway. The products were matched to
each other in terms of taste, appearance, smell and ﬂavour
by adding cherry jam. The ﬁnished products were
manufactured and quality controlled by the Agricultural
University of Norway, A˚s, Norway. The study products
were presented in identical, unmarked (except for subject
number) containers. A detailed comparison of the contents
of each study treatment is presented in Table 1.
Statistical analysis
This was a randomised, placebo-controlled, double-blind,
parallel-group, single-centre study. It was estimated that
with approximately seventy patients in each group, the
power to detect a 10% difference in LDL-cholesterol
between the two study groups would be at least 90%
with a 5% signiﬁcance level (two-sided). Neither the
investigators nor the patients knew the computer-generated
randomisation code, block size or the results of the blood
lipid concentrations until after the statistical analysis. Stat-
istical analyses were conducted before breaking the ran-
domisation code.
The primary analysis was undertaken on a modiﬁed inten-
tion-to-treat population, deﬁned as those subjects who
received the study treatment for at least 2 weeks. Changes
in serum lipids over time were analysed by a mixed model
for unbalanced repeated measurements employing the
SASw 6.12 software (SAS Institute, Cary, NC, USA). Para-
meters were estimated by the method of restricted maximum
likelihood, and an unstructured covariance matrix was
applied. The model included time and treatment group as
themain effects and in addition the interaction between treat-
ment and time. When no statistically signiﬁcant interaction
was found, the interaction term was excluded from the
model. The last measurement before the start of treatment
was included as a covariate in the model. Total cholesterol,
HDL-cholesterol, non-HDL-cholesterol, LDL-cholesterol,
LDL:HDL ratio, total:HDL-cholesterol ratio and
triacylglycerols were analysed separately. Analysis of
covariance was used to estimate the effect of treatment on
homocysteine. The active soya treatment and placebo
were compared for a total of eight efﬁcacy variables.
In order to assess the robustness of the results, we con-
ducted secondary analyses. In the intention-to-treat popu-
lation, missing values were substituted according to the
last-observation-carried-forward method. In addition, the
per-protocol population consisting of study completers
only (i.e. ﬁfty-three subjects in the active soya group and
seventy in the placebo group) was analysed. Both second-
ary analyses demonstrated that the data obtained in our
primary analysis were robust and consistent.
Table 1. Contents of the yoghurt products
Active soya Placebo
Energy (kJ) 1484 994
Protein (g)
Isolated soya protein* 20·7 0
Milk protein 0 12·2
Total ﬁbre (g) 4·5 0
Fat (g) 2·84 1·6
Soya lecithin (g) 1·76 0
*Standardised as 3·7mg isoﬂavones/g soya protein.
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Ethics and administration
The study protocol and informed consent form were
approved by the ethics committee of the Joensuu
Health Centre, Joensuu, Finland. An independent con-
tract research organisation (Smerud Medical Research
International AS, Oslo, Norway) was responsible for
monitoring the study according to the International Con-
ference on Harmonization guidelines on good clinical
practice principles (European Agency for the Evaluation
of Medicinal Products, 1996) and for overall quality
assurance.
Results
A total of 146 subjects were admitted for the screening of
selection criteria, and were subsequently randomised to
receive the study products. Three subjects withdrew
their consent either before or immediately after taking
the ﬁrst dose. Hence 143 subjects, sixty-nine in the
active soya group and seventy-four in the placebo
group, have been included in the analysis of efﬁcacy.
Fig. 1 shows the ﬂow of participants through each stage
of the study. The two groups were well matched at base-
line (Table 2) for sex, age, body weight, BMI, blood
pressure, heart rate as well as for cigarette smoking and
alcohol use.
A signiﬁcant proportion of patients dropped out from the
study during the intervention period, as they did not toler-
ate the product. The difference between the study groups
was statistically signiﬁcant (P¼0·03) as fourteen subjects
(20·3%) from the active soya group, and three (4·1%)
from the placebo group dropped out, respectively. The
reason for withdrawal was either ‘refusal to take more
study product’ or ‘adverse events’. The subjects com-
plained about nausea, vomiting, stomach pain and a feeling
of stomach swelling, but these symptoms were usually
mild and transient. Furthermore, three of the subjects in
the active soya group who refused to continue taking the
study product did so after a contamination (mould
growth) was found in their yoghurt cups. There were
no signiﬁcant changes in any of the haematological or
biochemical laboratory variables.
Lipid variables
Table 3 shows the mean screening and baseline concen-
trations for the lipid efﬁcacy variables. Our statistical
model incorporated the results from all biweekly visits,
and the mean changes from baseline as well as the esti-
mated difference in reductions, are also presented. The
difference between the active soya treatment and the pla-
cebo was statistically signiﬁcant for total cholesterol-,
LDL-cholesterol-, and non-HDL-cholesterol-lowering and
for the total:HDL-cholesterol and LDL:HDL-cholesterol
ratios, whereas no differences for HDL-cholesterol
changes, or for triacylglycerols or homocysteine were
found. The serum concentrations over time for total choles-
terol and LDL-cholesterol are presented in Fig. 2. The
reduction occurred rapidly, within 1–2 weeks, and contin-
ued up to 8 weeks. Upon withdrawal after 8 weeks of the
study products, serum concentrations for both groups
returned to their baseline values.
Isoﬂavone levels
After therapy, the genistein levels were 762·1 (SD
1001·9) nmol/l in the active soya group and 7·8 (SD
11·7) nmol/l in the placebo group. For daidzein, the after-
therapy levels were 127·0 (SD 120·5) and 2·6 (SD
5·1) nmol/l, for the active soya and placebo groups, respect-
ively. These results conﬁrmed that genistein and daidzein
were indeed good means to distinguish those patients being
reasonably compliant with taking study products and those
who were not.
Haemodynamics
There were no signiﬁcant changes in blood pressure or
heart rate (data not shown) for either group during the
study. The active soya group had systolic blood pressure
of 130·0 (SD 15·8) mmHg at screening, 129·6 (SD 15·8)
mmHg after the 8-week intervention, and 129·9 (SD 14·2)
mmHg at 4 weeks after the study. However the results in
the placebo group were 132·4 (SD 17·1) mmHg at screen-
ing, 131·3 (SD 15·7) mmHg after 8 weeks intervention,
and 132·1 (SD 19·1) mmHg at 4 weeks after the interven-
tion. For diastolic blood pressure, the ﬁndings were 80·5
(SD 8·7) mmHg at screening, 80·6 (SD 8·2) mmHg after
Fig. 1. Study ﬂow-chart and number of subjects at each study stage.
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the 8-week intervention, and 80·1 (SD 8·6) mmHg at 4
weeks after the study for the active soya group. The corre-
sponding results in the placebo group were 81·1 (SD 9·4)
mmHg at screening, 81·3 (SD 9·7) mmHg after the
8-week intervention, and 80·1 (SD 9·9) mmHg at 4 weeks
after the intervention.
Body weight
Body weight was measured in every single clinic visit for
all patients. The groups were comparable at baseline, and
there were no signiﬁcant changes in mean weight through-
out the duration of the study. Females in the active soya
group had a slight mean change from 72·7 (SD 15·3) to
73·7 (SD 15·8) kg compared with a similarly negligent
change from 68·7 (SD 12·8) to 69·6 (SD 12·9) kg in the
placebo group. For males, the mean change was in the
opposite direction, from 82·2 (SD 9·0) to 79·9 (SD
17·8) kg in the active soya group and from 84·5 (SD 10·8)
to 82·6 (SD 18·9) kg in the placebo group.
Discussion
The present 8-week diet intervention trial in subjects with
hypercholesterolaemia demonstrated that a product based
on isolated soya protein with standardised levels of isoﬂa-
vones, cotyledon soya ﬁbres and soya phospholipids had
modest, but clinically signiﬁcant, lipid-lowering effects
compared with a placebo. The ﬁndings conﬁrm that in a
population with mild-to-moderately elevated plasma
lipids, effects on cholesterol lowering can be obtained
with a functional food.
Law et al. (1994) have shown that for mild-to-moderate
hypercholesterolaemic subjects, a 10% reduction in total
cholesterol lowers the risk of cardiovascular events by up
Table 2. Subject characteristics at baseline
(Mean values and standard deviations)
Active soya Placebo
Mean SD Mean SD
Patients (n)
Total 69 74
Males 33 34
Females 36 40
Age
Range (years) 30–70 35–70
Median (years) 58 58
Weight (kg)
Males 82·2 9·0 84·5 10·8
Females 72·7 15·3 68·7 12·8
BMI (kg/m2)
Males 26·6 2·9 27·1 3·7
Females 28·1 5·3 26·4 5·0
Systolic blood
pressure (mmHg)
130·0 15·8 132·4 17·1
Diastolic blood
pressure (mmHg)
80·5 8·7 81·1 9·4
Heart rate (beats/min) 70 10 69 10
Daily cigarette smokers
(% of patients)
13 11
Alcohol users
(% of patients)
32 30
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to 50% for a 40-year-old individual, and gradually less for
older subjects. However, extrapolating risk reduction based
on cholesterol alone is probably much too crude. With
regard to the risk of CHD, it is not known whether other-
wise healthy subjects would beneﬁt from taking soya ﬁbre
for several years; neither has long-term safety been studied
carefully.
Despite the test product being a dietary supplement by
classiﬁcation, we designed and conducted the study accord-
ing to the guidelines for developing medicinal products.
We employed both general principles (International Con-
ference on Harmonization topics E6, E8, E9, and E10;
European Agency for the Evaluation of Medicinal
Products, 1996, 1997, 1998, 2000) and speciﬁc ones for
the treatment of dyslipoproteinaemia (European Agency
for the Evaluation of Medicinal Products, 2001). It is
well known, and comprehensively reviewed by Sandstro¨m
(1995), that dietary supplement studies include a number of
confounding factors, since such intake most often includes
other dietary components as well. Seasonal or dietary adap-
tation, as well as inaccuracy of self-reporting of dietary
data, further complicate the analysis. Strict dietary food
control could have controlled changes of individual food
intake. The study intended to diminish any effect on
normal life settings. The effect of keeping a food diary
could have introduced an adverse effect on normal life of
these subjects compared with only frequent visits to the
study nurse, and was considered inappropriate.
As the present study was an early proof-of-concept one,
we aimed to include subjects with the highest probability
of showing an effect, and thus we included subjects with
as high lipid levels as possible. However, the subjects
were not so hypercholesterolaemic that intervention with
a statin or another licensed lipid-lowering drug would be
mandatory according to public guidelines at the time of
planning the study. The meta-analysis by Anderson et al.
(1995) showed that sex does not affect the response to
soya protein, but whether isoﬂavones could have lesser
effects in women with premenopausal oestrogen levels
was not addressed in their paper. Consequently, we chose
not to include this patient group in the present study.
The placebo was a standard low-fat yoghurt available on
the consumer market. Cherry jam was added to this
yoghurt in order to make it similar to the soya yoghurt.
The two products were not completely identical in fat con-
tent as there were manufacturing obstacles to maintain
blinding in terms of appearance, smell and taste if the fat
content should be kept identical. Obviously, this difference
in fat content may explain some of the differences, and
needs careful considerations in future studies. Whether
this choice was truly a placebo is also questionable, as
the placebo group also showed a mean reduction in
lipids, and regression to the mean would also be one poss-
ible explanatory factor.
For the primary efﬁcacy variable (LDL-cholesterol),
there was a highly signiﬁcant difference between the
active soya treatment and the placebo corresponding to a
mean reduction from baseline of 0·42mmol/l (correspond-
ing to a 7·8% difference in reduction) for the subjects
taking active soya. Similar results, demonstrating a consist-
ent beneﬁcial effect, were also seen for total cholesterol and
non-HDL-cholesterol, as well as for the LDL:HDL-choles-
terol and total:HDL-cholesterol ratios. The present results
suggest that the effect of soya protein and ﬁbre are some-
what higher than seen in previously reported studies with
the same duration of treatment (Anderson et al. 1995;
Baum et al. 1998; Wong et al. 1998; Crouse et al. 1999;
Merz-Demlow et al. 2000; Teixeira et al. 2000).
Fig. 2. Serum concentration v. time for total cholesterol in the active soya group (–W–), total cholesterol in the placebo group (- -D- -),
LDL-cholesterol in the active soya group (–X–), and LDL-cholesterol in the placebo group (- -O- -). Mean values are shown, with standard
deviations represented by vertical bars.
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The rapid onset of the cholesterol-lowering effect was
striking, even if this phenomenon is well known from other
dietary intervention studies. About half of the effect after 8
weeks was seen already after the ﬁrst week of intervention.
These early lipid changes could be due to weight loss, but
upon inspection we were not able to explain our ﬁndings
by the weight data. This rapid onset of effect may prove ben-
eﬁcial to patients who need motivation in the early phases of
treatment, and in particular for those patients who are not
able to comply with lifestyle modiﬁcation programmes.
In recent years, homocysteine has been introduced as a
potential risk factor for atherosclerosis (Boushey et al.
1995; Gerhard & Duell, 1999; Wald et al. 2002). A pre-
vious study with Abacorw in a ready-to-mix beverage
form (Tonstad et al. 2002) had demonstrated favourable
effects with a daily dose of 30–50 g soya protein, but the
present results were not able to conﬁrm this effect in the
yoghurt formulation.
It has been shown that related products based on soya
are efﬁcient in reducing weight and maintaining the
weight loss over time (Ro¨ssner & Flaten, 1997; Ryttig
et al. 1997). One could also have expected some weight-
reduction beneﬁt from participating in the present study
as the subjects were asked to follow a standardised healthy
diet scheme. We expected that subjects who are followed
carefully with bi-weekly weight measurements in a medi-
cal clinic by health professionals would be likely to
adhere truthfully to the dietary programme and in general
lose weight because of greater focus on and awareness of
a healthy lifestyle. The present results did not demonstrate
any signiﬁcant weight reduction even if a slight tendency
in the male groups was noted, but 8 weeks may be too
short to see any effects.
The yoghurt formulation used in the present study was
not well tolerated. Microbiological (mould) contamination
in some of the soya yoghurt cups from one shipment partly
explained the dropout problems in the active soya group.
However, even when correcting for this, the number of
dropouts and complaints due to gastrointestinal symptoms
were higher in the active soya group. The high intake of
ﬁbre may partly explain the gastrointestinal symptoms
reported by some subjects. The usability of this prototype
product is also limited in practice because of the relatively
large volume of yoghurt, almost 300ml twice daily.
Whether the difference in yoghurt composition (energy
or fatty acids or fermenting organism) inﬂuenced the
results should be studied in later product development
and clinical investigations. A lower dose taken for a
longer term might be as or even more efﬁcient but this
remains to be conﬁrmed in further dose–response investi-
gations. Except for the gastrointestinal symptoms, both
study groups showed a similar tolerability proﬁle and the
study did not indicate any particular safety concerns. How-
ever, the present study was not designed to address the
safety issue speciﬁcally, and larger therapeutic use studies
or post-marketing surveillance must be undertaken in order
to shed more light on this aspect.
In conclusion, the present study supports a signiﬁcant
lipid-lowering effect of isolated soya proteins with
standardised levels of isoﬂavones, cotyledon soya ﬁbres
and soya phospholipids. Some product development is
recommended in order to avoid the gastrointestinal symp-
toms, and to reduce the volume to be ingested. Dependent
on evidence from conﬁrmatory and long-term trials, this
soya yoghurt might then be a ﬁrst intervention step in
hypercholesterolaemia in addition to general dietary
changes and possibly as an add-on to statin therapy. The
rapid onset of effect may prove particularly beneﬁcial to
patients who need motivation in the early phases of
intervention.
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